Benitec Biopharma Limited

Benitec Limited (ASX:BLT)(PINK:BNIKF) today announced that a key patent focused on producing Double-Stranded Nucleic Acid constructs for therapeutic and related applications of RNA interference (RNAi) was granted in New Zealand.

The Directors of Benitec Limited (ASX: BLT)(PINK: BNIKF) have decided to suspend the planned non-renounceable rights issue. The underwriter wants Benitec to restructure its relationship with CSIRO before proceeding with the raising of funds (as announced to the ASX on Friday 16 May 2008) as it believes this will add further value to Benitec.

The Directors of Benitec Limited (ASX: BLT)(PINK: BNIKF) today announced that the Company proposes to raise approx $5.1 million (before expenses to the offer) by undertaking a fully underwritten non-renounceable rights issue.

Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX: BLT)(PINK: BNIKF) has secured further intellectual property rights that underpin its HIV/AIDS lymphoma therapeutic currently under going clinical trials at City of Hope in Duarte, California. The therapeutic uses RNAi technology covered by Benitec's patent portfolio.

The Directors of Benitec Limited (ASX: BLT) announced today that the US Supreme Court met on Friday to decide on Benitec's Motion of Respondent for Leave to File a Brief in Opposition Under Seal. Today Benitec was not only notified that the motion was granted. The Court also stated that "The petition for a writ of certiorari is denied."

Benitec Limited (ASX: BLT) - Pfizer Granted Non-Exclusive Worldwide License to use Benitec Technology - Sue MacLeman, CEO; Boardroomradio is pleased to announce that Benitec Limited (ASX: BLT) has published an audio file.